Acebutolol hydrochloride
Code | Size | Price |
---|
TAR-T1012-1mL | 1 mL * 10 mM (in DMSO) | £95.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T1012-50mg | 50mg | £104.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T1012-100mg | 100mg | £109.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T1012-200mg | 200mg | £119.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
Acebutolol acts as a cardioselective beta-adrenergic antagonist with little effect on bronchial receptors and has intrinsic sympathomimetic properties. Acebutolol Hydrochloride is the hydrochloride salt form of acebutolol, a synthetic butyranilide derivative with hypotensive and antiarrhythmic activity. Having stabilizing and quinidine-like effects on cardiac rhythm, Acebutolol is used in ventricular arrhythmias. Other indications include hypertension, alone or in combinations with other agents.
CAS:
34381-68-5
Formula:
C18H29ClN2O4
Molecular Weight:
372.89
Pathway:
GPCR/G Protein; Neuroscience
Purity:
1
SMILES:
Cl.CCCC(=O)Nc1ccc(OCC(O)CNC(C)C)c(c1)C(C)=O
Target:
Adrenergic Receptor
References
1. Street JA, et al. Eur J Pharmacol, 1984, 102(2), 315-324.
2. Mauri?ge P, et al. J Lipid Res, 1988, 29(5), 587-60
3. Seifert T, et al. Chem Phys Lipids, 1997, 85(1), 13-21.
4. Piquette-Miller M, et al. Biopharm Drug Dispos, 1997, 18(6), 543-556.
5. Mostafavi S, et al. Biopharm Drug Dispos, 2000, 21(4), 121-128.